Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Here’s why the Volpara (ASX:VHT) share price is jumping

The Volpara Health Technologies Ltd (ASX:VHT) share price is up more than 3% after revealing a major contract win in Australia. 

The Volpara Health Technologies Ltd (ASX: VHT) share price is up more than 3% after revealing a major contract win in Australia.

Volpara is a health technology software company founded in 2009. Its software is used for screening clinics to provide feedback on breast density, compression, dose and quality. Its enterprise-wide practice management software helps with productivity, compliance, reimbursement and patient tracking.

Australian contract win

Volpara said that it has signed a five year software as a service (SaaS) contract with BreastScreen Queensland, after a successful pilot trail with BreastScreen Queensland on the Gold Coast.

BreastScreen Queensland is the third largest public breast screening programme in Australia. The terms and conditions of the contract with BreastScreen Queensland are confidential.

The contract, which is initially for Volpara’s quality assurance platform, VolparaEnterprise, allows for the expansion of services to include VolparaDensity and VolparaLive.

The initial stage will involve the roll-out of VolparaEnterprise to 11 BreastScreen Queensland services operating in Brisbane and elsewhere in the state. The BreastScreen Queensland services comprise 69 gantries and 43 sites that include 10 mobile units, covering 171 radiologists and technologists. The roll-out has already begun and Volpara expects it to go live in early 2021.

Management comments

Volpara CEO Dr Highnam said: “Public breast cancer screening programmes around the world do a fantastic job at reducing deaths from breast cancer, and they do so by operating under the strictest quality control, which can make change difficult. 

But, we are delighted to now have BreastScreen Queensland signing up to use our software, making it the second major public breast cancer screening programme in Australia signed up to Volpara products. This is news that will resonate around the world, and we are extremely pleased that our software will be helping women in the fight against breast cancer, including women in the lives of many of our long-term investors.”

Summary thoughts

These types of deals are very promising. Not only is it a good deal itself, but management can point to this contract when pitching to other large potential customers around the world, leading to more good contract wins and more growth.

Volpara is a very compelling business with a very high gross profit margin, expanding market share and growing average revenue per user (ARPU). I think it could be one to keep an eye on over the coming years.

Other ASX growth shares in the tech space could also make great investment such as Pushpay Holdings Ltd (ASX: PPH) and Xero Limited (ASX: XRO), though Xero is pretty pricey right now.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content